logo
NHS struggles to turn cash into care

NHS struggles to turn cash into care

Times4 hours ago

The NHS is one of the worst health systems in the western world at converting money into better care, a report by the TaxPayers' Alliance suggests.
Researchers examined data from the Organisation for Economic Co-operation and Development to compare 13 health systems, including in the UK, Canada, Australia, France and Germany, and found the UK had the lowest life expectancy and highest rates of avoidable deaths.
It showed that the NHS struggled to convert funding into more resources such as doctors, nurses, hospital beds or scanners, with two thirds of its budget swallowed up by staffing costs, including pensions.
The TaxPayers' Alliance report said: 'Without a serious improvement in productivity, the extra cash released by Rachel Reeves is unlikely to be noticed by patients.'
The NHS was handed an extra £29 billion in Labour's spending review this month and is on track to take up 50 per cent of all public spending by the end of the decade.
However, experts have warned that the money will be wasted unless the NHS can improve efficiency and productivity.
The TaxPayers' Alliance report said the UK ranked third highest out of the 13 countries in terms of how much is spent on health as a percentage of GDP. However, it only ranked 12th by the metric of converting money into resources that can help treat patients.
• The Times View: Wes Streeting must transform Britain's crippled health services
The NHS also ranked 11th when it came to capital spending on new technology and hospitals. The researchers said priority 'must be given to capital investment over further expansions on staff' in order to boost productivity.
The figures showed that the NHS spends 64 per cent of its budget on staffing, far more than comparable countries such as New Zealand or Ireland, which spend 42 per cent and 33 per cent respectively.
This was largely due to generous public-sector pensions for doctors and other NHS staff. There have been calls for reforms to rebalance NHS remuneration away from pensions towards take-home pay.
Last year a report by Lord Darzi highlighted a collapse in NHS productivity in the past decade. It found that the hospital workforce had risen by 17 per cent between 2019 and 2023, yet output had not risen at nearly the same rate, which was largely due to a failure to invest in upgrading equipment and buildings.
• Darzi report: money alone can't cure what ails NHS
Darwin Friend, head of research of the TaxPayers' Alliance, said: 'Our comprehensive analysis of healthcare productivity is by no means all doom and gloom, with the NHS clearly performing well in some areas, particularly when looking at its use of existing resources.
'But it does paint a bleak picture for taxpayers, given the overwhelming evidence to suggest that the vast extra funding announced at the spending review will simply be throwing good money after bad without more fundamental and far-reaching reform.
'If the government wants to deliver on its promises, it will need to be far braver than politicians have been and consider changes previously considered unpalatable, including regional pay bargaining, the prioritisation of capital spending and a role for more insurance-based financing.
'It will also have to face down demands for increased pay, given the disproportionate amount of the NHS budget that is swallowed up by staffing.'
Kristian Niemietz, head of political economy at the Institute of Economic Affairs, said: 'In state-run health systems like the British NHS, there is often a temptation to prioritise day-to-day spending over long-term investment. Politicians know that by the time the detrimental effects become apparent, somebody else will be in charge and it will be somebody else's problem.
'The paper also shows that while the NHS cannot be described as 'underfunded', it is in a very real sense under-resourced. These are not the same thing — a pile of cash does not magically transform itself into a doctor, a nurse or an MRI scanner. The NHS is remarkably bad at converting its financial resources into medical inputs.'
The report analysed data from 13 countries: Portugal, South Korea, Norway, Germany, Spain, Australia, Ireland, Italy, Denmark, New Zealand, France, the UK and Canada.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mounjaro weight loss jab: All you need to know
Mounjaro weight loss jab: All you need to know

Western Telegraph

time44 minutes ago

  • Western Telegraph

Mounjaro weight loss jab: All you need to know

Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? The jab makes you feel fuller for longer and therefore less hungry (PA) Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Mounjaro is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested (Alamy/PA) Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

Mounjaro weight-loss injections now available through GP
Mounjaro weight-loss injections now available through GP

Times

timean hour ago

  • Times

Mounjaro weight-loss injections now available through GP

Weight-loss injections will be prescribed by GPs for the first time this week as the NHS begins a mass rollout of the drugs. About 220,000 severely obese people with the 'greatest need' will receive Mounjaro, also known as tirzepatide, from their doctor over the next three years. Weight-loss drugs such as Wegovy and Mounjaro had previously only been available through specialist NHS weight-loss clinics, which have long waiting lists. • Our Mounjaro diaries: six months on, has it changed our lives? From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. The drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes, high blood pressure, heart disease and obstructive sleep apnoea. After the initial phase, expected to take three years, Mounjaro will then be offered to about three million more patients with a BMI of more than 35. The drug is already taken by about 1.5 million people in the UK, the vast majority of whom buy it privately through online pharmacies for about £200 a month. Weight-loss jabs through the NHS have so far been limited to about 50,000 patients. Wes Streeting, the health secretary, said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology and knowledge to end the obesity epidemic if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best' and this government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming ten-year plan will deliver.' Doctors have raised concerns about the extra workload. Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'While we recognise the potential benefits of weight-loss drugs, we know many GPs are concerned about the implications of the rollout of weight-loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments.' She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight-loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight-loss drugs, with community-based services now able to offer this treatment. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health — and greater access to weight-loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight-loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'

Mounjaro weight loss jab: All you need to know
Mounjaro weight loss jab: All you need to know

Glasgow Times

timean hour ago

  • Glasgow Times

Mounjaro weight loss jab: All you need to know

Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? The jab makes you feel fuller for longer and therefore less hungry (PA) Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Mounjaro is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested (Alamy/PA) Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store